Trial Profile
An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2022
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Aragon Pharmaceuticals
- 22 Nov 2022 Status changed from active, no longer recruiting to completed.
- 30 Sep 2022 Planned End Date changed from 15 Oct 2022 to 15 Oct 2023.
- 04 Nov 2021 Planned End Date changed from 1 Oct 2022 to 15 Oct 2022.